Picking stocks at small cap stage for potential 100x. Medical field.

California, USA
Joined October 2012
Gm, $PRME will cure most genetic diseases.
30
1,689
The only real risk in life is being a pussy, and not taking a risk.
5
2
62
3,208
“Rate limiting factor will be prescribers.” When peptides hit the market, people will flock to the most reputable companies for distribution. $HIMS $ENHA
Soon, possibly within the next two weeks compounding pharmacies in the United States will be able to make the majority of the Peptides people want - legally. I’m talking easily 500,000 to 1,000,000 bottles per week in a 503A compounding facility, like Strive, Empower, Olympia, ReviveRx etc The infrastructure has been being built out for the past six months. They’ve confirmed to me personally. The rate limiting factor will indeed be prescribers. Hence @peptavo
1
2
26
1,990
Trav retweeted
Good morning, the Bolsheviks were jews
39
181
1
2,296
13,791
Increased share count in $NAUT by 44.71%.
10
5
109
9,472
All my old $PLTR friends hate me now cause I call it a genocidal company. Actually a blessing cause shows their true character.
11
32
5,754
Disease agnostic therapeutic genome editing. This is why $PRME has 100x potential.
2
3
61
5,486
If you’re valuing start up companies based on spreadsheet analysis you’ll miss 99% of 100x’ers.
3
1
24
5,400
My port now covers the new wave of medicine that will replace the “keep you sick” companies we have now- 1) $HIMS - distribution, peptides, primary care within minutes. And for cheap. 2) $ABCL - frontier of antibody therapy discovery, and development. This is the new direction of pharma, and Abcellera is the best at it. 3) $PRME - prime gene editing, best tech in the space. Looking to potentially cure 89% of genetic diseases at the source. 4) $NAUT - mapping the proteome. Also best tech in the space. Essential to improving medicine development, lowering the “shot in the dark” aspect of drug discovery. This will improve the efficiency, and accuracy of finding the best new drugs. And ideally prevent wasteful failed clinical trials. 5) $ENHA - on the frontier of performance medicine. Running clinical trials on elite athletes, and gathering data on athletes at a level that has never been done before in relation to enhancers. Simultaneously providing a major platform for athletes to safely enhance, and fill a market of yearly Olympic type games. Which can expand to many disciplines including mma, boxing etc,
8
5
2
148
10,047
Opened position in $NAUT at 6.4% of port.
Someone explain $NAUT to me like I’m six please.
16
3
122
9,244
BPC-157 would help boomers the most. A 67 y/o I recommended to get on BPC-157 was also recommended hand surgery by his doctor. He also could not throw a baseball because he had shoulder issues. Today I got a text that he throws a baseball with his grandson, and his hand pain is completely gone. And that’s after just a few doses. $HIMS $ENHA
4
3
76
3,712